Scholar Rock's second quarter saw the relatively early-stage company post no revenue and a net loss of over $110 million, or ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for ...

Operator: Good morning, ladies and gentlemen, and welcome to the Scholar Rock Second Quarter 2025 Business Update Conference Call. [Operator Instructions] This call is being recorded […] ...

No revenue was recorded as the company remains pre-commercial, in line with analyst expectations. R&D and G&A expenses surged 47% and 191% year over year as apitegromab advanced toward anticipated U.S ...

Scholar Rock Holding SRRK -4.80% + Free Alerts has outperformed the market over the past 5 years by 7.22% on an annualized basis producing an average annual return of 21.06%. Currently, Scholar Rock ...

Q2 2025 Management View CEO David L. Hallal emphasized Scholar Rock is “scaling for the next phase of growth as a commercial stage fully integrated global biopharmaceutical company.” He outlined three ...

MONDAY, Aug. 11, 2025 (HealthDay News) — Spinal muscular atrophy (SMA) is a genetic neuromuscular disease affecting ...

Explore Scholar Rock Holding stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for SRRK.

Norman Finkelstein, a political scientist and activist known for his fiery on-air criticisms of Israel’s ongoing genocide in ...

Anyone who’s attended college knows juggling a hefty schedule and making time for a social life can be hard, but one UA ...